Jeff Posakony, Ph.D.

Jeff Posakony, Ph.D. has extensive experience in the pharmaceutical and biotechnology industries. Jeff began their career in 1992 as a Graduate Student at The University of British Columbia. In 1998, they became a Postdoctoral Fellow at the University of Washington, where they developed routes to [18F]-labelled ligands to image subtypes of the beta-adrenergic receptors. In 2001, they became a Research Specialist and Postdoctoral Fellow at the Fred Hutchinson Cancer Research Center. In 2011, they became a Staff Scientist at the National Institutes of Health, where they developed synthetic phosphoamino-carbohydrates for studying the GlmS Ribozyme in the Ferre-D'Amare lab. In 2013, they founded Ziel-Rx, LLC and became a Senior Scientist at Kineta, Inc. In 2016, they became a Group Leader at Kineta, where they were the medicinal chemistry and formulation Lead for Kineta’s peptide-based chronic pain asset. In 2018, they became an Associate Director, Translational Development at Kineta, Inc., where they were the Chemistry and Manufacturing and Controls (CMC) Lead for Kineta’s late stage preclinical and clinical-stage assets. In 2021, they became the Director at AltPep Corporation.

Jeff Posakony, Ph.D. obtained their Ph.D. in Chemistry from The University of British Columbia in 1998. Jeff had previously spent a year at the University of Konstanz in 1991. Jeff received their B.S. in Chemistry from Oregon State University in 1990.